BioSenic S.A. (EBR:BIOS)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.0025
+0.0001 (4.17%)
Oct 9, 2025, 5:35 PM CET
4.17%
Market Cap1.63M
Revenue (ttm)2.67M
Net Income (ttm)-7.44M
Shares Out652.86M
EPS (ttm)-0.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume889,196
Average Volume1,091,415
Open0.0026
Previous Close0.0024
Day's Range0.0024 - 0.0027
52-Week Range0.0012 - 0.0160
Beta-2.43
RSI49.11
Earnings DateOct 27, 2025

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company’s technologies include arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops ArsciCor, an oral medication in Phase III clinical trial and for the treatment for chronic graft-versus-host disease; JTA-004, an intra-articular injectable ... [Read more]

Industry Biotechnology
Sector Healthcare
CEO François Rieger
Country Belgium
Stock Exchange Euronext Brussels
Ticker Symbol BIOS
Full Company Profile

Financial Performance

In 2023, BioSenic's revenue was 336,000, an increase of 13.51% compared to the previous year's 296,000. Losses were -28.78 million, 1310.0% more than in 2022.

Financial Statements

News

There is no news available yet.